Announcements Trials
Browse Landscape

Phase

Phase 1 7

Status

Completed 4Terminated 2Unknown 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 7

Sponsor

Cancer Type

Other solid neoplasm 7

Conditions

Neoplasms 2012Carcinoma, Non-Small-Cell Lung 1228Breast Neoplasms 1215Leukemia, Myeloid, Acute 967Neoplasm Metastasis 902Melanoma 778Colorectal Neoplasms 752Multiple Myeloma 725Lymphoma 725Ovarian Neoplasms 675Pancreatic Neoplasms 665Lymphoma, Non-Hodgkin 659Prostatic Neoplasms 657Recurrence 637Precursor Cell Lymphoblastic Leukemia-Lymphoma 585Lung Neoplasms 560Leukemia, Lymphocytic, Chronic, B-Cell 555Glioblastoma 527Leukemia 486Lymphoma, Large B-Cell, Diffuse 440Lymphoma, Follicular 419Brain Neoplasms 415Squamous Cell Carcinoma of Head and Neck 389Stomach Neoplasms 387Carcinoma, Renal Cell 385Myelodysplastic Syndromes 382Carcinoma, Hepatocellular 368Advanced Solid Tumors 357Lymphoma, Mantle-Cell 345Glioma 343

Interventions

capivasertib 1atezolizumab 1N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide 1N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 1Midazolam 1L19-IL2 immunocytokine 1Itraconazole 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 1 × Solid Tumour × Clear all
NCT06488716 2025-12-24

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors

Genentech, Inc.

Phase 1 Terminated
12 enrolled
Other solid neoplasm

Solid Tumour

NCT04958226 2024-01-25

A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
21 enrolled
Other solid neoplasm

Solid Tumour

NCT04121910 2020-01-23

A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole

AstraZeneca

Phase 1 Completed
16 enrolled
Other solid neoplasm

Solid Tumour

NCT02086721 2017-05-31

L19-IL2

Maastricht Radiation Oncology

Phase 1 Completed
18 enrolled
Other solid neoplasm

Solid Tumour

NCT01516645 2017-03-16

Phase 1 Study of KHK2898 in Subjects With Advanced Solid Tumors

Kyowa Kirin Co., Ltd.

Phase 1 Terminated
14 enrolled
Other solid neoplasm

Solid Tumour

NCT01226407 2012-12-31

Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile

CrystalGenomics, Inc.

Phase 1 Unknown
36 enrolled
Other solid neoplasm

Solid Tumour

NCT01300468 2011-02-21

Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors

Nerviano Medical Sciences

Phase 1 Completed
38 enrolled
Other solid neoplasm

Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡